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(e.g., Nerve block)Abstract Aim: To evaluate the feasibility and efﬁcacy of ultrasound guidance technique for the
treatment of meralgia paresthetica (lateral femoral cutaneous neuropathy).
Methods: 25 patients (10 males and 15 females); age 17–68 years; with meralgia paresthetica are
diagnosed clinically by electromyography. A needle was inserted targeting the LFCN with ultra-
sound guidance, treatment with perineural injection of 2 mL of methylprednisolone acetate
(40 mg/mL) and 8 mL of mepivacaine, 2%, under ultrasound guidance was performed.
Main outcome measurements included the technical success of the procedure, regarding relief of
symptoms (pain, burning sensation, and paresthesia) and change in the quality of life.
Results: Successful nerve block of the LFC nerve was achieved in 24 patients while 1 patient
remained with mild VAS after third injection which disappeared two months later. Three patients
underwent one injection, 6 two injections and 16 three injections with intervening period of 2 weeks
between the ﬁrst and second injections and one month between the second and third.
Conclusions: Ultrasound-guided perineural injection of the LFC nerve is quick, simple, economi-
cal, and effective in treatment of meralgia paresthetica.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.1. Introduction
The lateral femoral cutaneous nerve (LFCN) is a pure sensory
nerve that originates from 2, 3 lumbar nerves and emergesfrom the side of the psoas major and passes the iliacus diago-
nally toward the ASIS. It then passes above, below or between
the inguinal ligament, above the Sartorius and into the subcu-
taneous tissue of the femoral region. Then it is divided into
anterior and posterior division: the front controls the frontal
femoral region up to the knee area, the rear controls the lateral
femoral region up to the greater trochanter area (1).
Meralgia paresthetica is characterized by pain or paresthe-
tica along the lateral femoral cutaneous nerve (LFCN) and is
caused when this nerve is entrapped by ﬁbrosis or various
other reasons (2).
Fig. 2 The lateral femoral cutaneous nerve appears as an oval
shaped structure (hand arrow).
Fig. 3 The tip of the needle piercing the fascia lata just lateral to
the LFC nerve (arrow).
1128 S. Khodair, R. ElshafeyCommon causes of this compression include any condition
that increases pressure on the groin, including: tight clothing,
obesity, pregnancy, scar tissue near the inguinal ligament,
due to injury or post-surgery, walking, cycling or standing
for long periods of time and nerve injury, which can be due
to, for example; diabetes or a seat belt injury after a motor
vehicle accident (3).
Ultrasound nowadays is being developed into a powerful
tool that can observe very small peripheral nerves. Ultrasound
can conﬁrm the target nerve and surrounding structures so
diagnosis is more accurate, additional damage is reduced dur-
ing administration of medication and injection of steroids and
local anesthetic agent can be done at the exact location. Com-
pared to blind blocks, the amount of local anesthetic agent can
be reduced, lessening systemic toxicity from the local anes-
thetic agent (4,5) (Figs. 1 and 2).
It has recently been suggested that ultrasound guidance can
facilitate blockage of the nerve for diagnostic and therapeutic
purposes and may be particularly beneﬁcial in patients with
challenging surface anatomic landmarks and when low volume
injections are desired (6).
Blockage of the lateral femoral cutaneous nerve (LFCN) is
performed for therapeutic management of meralgia parestheti-
ca and as a regional anesthetic technique. The conventional
technique is associated with high failure rates secondary to
variable LFCN anatomy (7).
By using a 7–14 MHz linear array ultrasound probe a cross-
sectional view of the LFCN was obtained by identifying the
anterior superior iliac spine, then the probe is moved in a med-
ial and caudal direction until the nerve was encountered. The
needle was advanced to the LFCN under ultrasound guidance
via a lateral to medial approach. Injection using dynamic
ultrasound demonstrated excellent perineural spread (7,8)
(Figs. 3 and 4).
A visual analog scale (VAS) is a measurement instrument
that tries to measure a characteristic or attitude that is believed
to range across a continuum of values and cannot easily be
directly measured. For example, the amount of pain that a
patient feels ranges across a continuum from none to an
extreme amount of pain. From the patient’s perspective this
spectrum is categorized as; none, mild, moderate and severe
degrees (9–11).Fig. 1 Transverse scan at the ASIS shows the ASIS is an
echogenic bridge-like structure producing intense posterior acous-
tic shadowing.
Fig. 4 The anechoic ﬂuid injected material (arrow head) is seen
surrounding the LFC nerve (arrow).It was to capture this idea of an underlying continuum that
the VAS was devised. Operationally a VAS is usually a horizon-
tal line, 100 mm in length, anchored by word descriptors at
each end. The patients mark on the line the point that they feel
represents their perception of their current state of pain (9).
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the left hand end of the line to the point that the patient marks.
The ﬁndings suggested that 100-mm VAS ratings of 0–4 mm
can be considered no pain; 5–44 mm, mild pain; 45–74 mm,
moderate pain; and 75–100 mm, severe pain (9).2. Patients and methods
Research Ethics Committee approval and informed consent
were obtained.
Between February 2012 and March 2013, twenty-ﬁve
patients (10 males and 15 females) with age ranging from
17to 68 years (mean 35.3 years) with meralgia paresthetica
were included in this prospective study.
Inclusion criteria were as follows: Patients had to have clin-
ical symptoms of meralgia paresthetica. The diagnosis of meral-
gia paresthetica was established from the following indicators:
- Clinical data.
- Physical examination: numbness, decreased sensation and
loss of sharp (pin-prick) sensation over distribution of lat-
eral femoral cutaneous nerve, trigger points along the ingui-
nal ligament that generated symptomatic pain when
pressured.
- No erythema, joint or limb deformity, or palpable mass.
- Normal straight leg raising test.
- Knee and ankle reﬂexes were normal and symmetrical.
- The ﬂexor and extensor muscles of the proximal and dis-
tal lower extremities
- Showed normal strength.
- Electromyographic ﬁndings (lateral cutaneous nerve
amplitude potential <10 lV, latency >3.5 ms, and nor-
mal thigh muscle).
At the time of examination, the visual analog scale (VAS)
of the patient was determined.2.1. Exclusion criteria
Abnormalities in lumbar, pelvic and hip X-ray, CT or MRI.
2.1.1. Technique
We used the same technique described by Tagliaﬁco et al. (12).
All examinations were performed by using a commercially
available scanner (Voluson Pro 730; General Electric, Milwau-
kee, WI) with a 7.5–12 MHz linear transducer. The perineural
injection technique involved the following:
First, the block area was sterilized with 10% povidone.
Under rigorous aseptic conditions, the transducer was inserted
into a sterile bag, and sterile gel was applied to it.
2.2. Location of the anterior superior iliac spine
Patient lies supine, the anterior superior iliac spine (ASIS)
is palpated and visualized with the ultrasound probe as a
hyperechoic structure with posterior acoustic shadowing, and
the transducer was placed over it. The lateral end of the probe
was placed on the anterior superior iliac spine, and the medial
end extended medially in an anatomic transverse plane.The medial end of the probe was angled slightly in a caudal
direction so the transducer was parallel with the inguinal
ligament.
The transducer was moved in a mediocaudal direction while
searching for the echo signature of the lateral femoral cutane-
ous nerve (The fascia lata, fascia iliaca and the LFCN located
in between the two fascias which appeared in cross section as
an oval hyperechoic structure containing several circular hypo-
echoic fascicles. This appearance has been likened to a honey-
comb and appears tubular on longitudinal images. Once the
LFCN is visualized in a transverse plane, the nerve should
be traced proximally and distally to conﬁrm its appropriate
course toward the lateral thigh.
2.3. Location of the puncture site
Axial sonographic sections were obtained on the anterior supe-
rior iliac spine, and once situated with the nerve in position
that allow easier needle access. The needle was inserted by a
lateral or medial approach. The approach was tailored depend-
ing on the position of the lateral femoral cutaneous nerve rel-
ative to the anterior superior iliac spine.
2.4. Perineural injection
Under aseptic conditions, after conﬁrming the location of the
LFCN, the operator advances the needle (by a freehand tech-
nique, one hand held the transducer, and the free hand inserted
the needle) under direct ultrasound visualization to the LFCN
while maintaining a short axis (transverse) view of the nerve.
The needle is advanced in a longitudinal view relative to the
transducer to ensure visualization of the entire needle. We also
applied a color Doppler box in the region of interest to exclude
any aberrant blood vessels. When the tip of the needle was in a
proper position, aspiration was made ﬁrst to exclude entrance
into blood vessels. In the ﬁrst time injection, local anesthetic
was only used (8 mL of mepivacaine, 2%) resulting in perineu-
ral spread that is visualized on ultrasound in a real time and
also the spread was traced caudally to conﬁrm successful
spread. When some patients needed second injection we then
performed percutaneous perineural injection of 2 mL of meth-
ylprednisolone acetate (40 mg/mL) and 4 mL of mepivacaine,
2%, using the same previous technique. Patients needing a
third injection were injected only 4 mL of mepivacaine, 2%.
2.5. Evaluation of outcome
Two parameters (lateral femoral cutaneous neuropathy symp-
toms and the inﬂuence of lateral femoral cutaneous neuropa-
thy on the global quality of life) were measured before the
ﬁrst treatment (at baseline) and after each time of injection
during follow-up as a 10-point visual analog scale ranging
from 0 (no symptoms) to 10 (intolerable symptoms) and on
the global quality of life ranging from 0 (no inﬂuence on qual-
ity of life) to 10 (very low quality of life).
The procedure was considered successful when an effective
block in the distribution of the lateral femoral cutaneous nerve
was obtained. The period between the ﬁrst and second injec-
tion was two weeks and between the second and third injection
was one month.
Table 1 Number of times of injections in meralgia cases.
Number of injections No. of cases %
1 3 12
2 6 24
3 16 64
Total 25 100
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Twenty-ﬁve patients (15 females and 10 males) were included
in the present study referred to the Radiodiagnosis and Imag-
ing Department from physical medicine and rehabilitation and
neurology departments with clinical manifestations of sus-
pected meralgia symptoms, proved by EMG.
Twenty-ﬁve patients’ (10 males and 15 females) age ranged
from 17 to 68 years (mean 35.3 years). Sixteen patients (64%)
were having age between 30 and 50 years. Three patients
(12%) submitted for single injection, six patients (24%) were
submitted for two sessions of injection, while the remaining
sixteen patients (64%) were submitted to three sessions of
injection (Table 1).
Three patients were presented (at baseline) with mild degree
of pain regarding VAS, 10 patients with moderate degree and
12 patients with severe degree. After the ﬁrst injection, all of
patients acquired relative improvement of the pain, they asked
for another visit after one week. After one week two out of
three patients were completely pain free while the other one
was still having mild pain. One patient out of ten with moder-
ate pain was pain free and the other nine patients were having
mild pain. Nine patients out of 12 patients with severe pain
acquired mild pain while the other three patients were having
moderate pain.
The second injected was submitted two weeks after the ﬁrst
one and the patients were asked for re-visit after one week of
injection; six patients were completely pain free, one of them
was having mild pain at the baseline and the other ﬁve were
having moderate pain at the baseline. Among other sixteen
patients, only one of them was still having moderate pain while
the remaining ﬁfteen were having mild pain.
After one month from the second injection, the third injec-
tion was done with its effect is evaluated one week later, twelve
patients were completely pain free, while 4 patients still having
mild pain, three of them were pain free one week lateral while
only one patients still acquired mild pain for two months later
before become pain free (Table 2).Table 2 VAS (lateral femoral cutaneous neuropathy symptoms) an
block in meralgia cases.
VAS at baseline VAS at ﬁrst injection V
Score (mean ± SD) No. of cases Score (mean ± SD) No. of cases S
Mild 2.3 ± 0.6 3 No 0.2 ± 0.2 3 N
Moderate 6.2 ± 0.77 10 Mild 1.3 ± 0.7 19 M
Severe 8.2 ± 0.6 12 Moderate 6 ± 0.5 3 M4. Discussion
Lateral femoral cutaneous nerve block for the treatment of
meralgia paresthetica is a commonly known treatment method
(2).
Entrapment neuropathies can manifest with confusing clin-
ical features and therefore are often under-recognized and
under-diagnosed at clinical examination (1).
In a study by Hospodar et al. the course of the nerve was
variable but was most commonly found 10–15 mm from the
anterior superior iliac spine, although it was found as far medi-
ally as 46 mm. In our study the location of lateral cutaneous
nerve is nearly not variable and it is present below the inguinal
ligament at its place above the Sartorius and below the tensor
fasciae latae (12).
Ng et al. investigated whether ultrasound was an accurate
tool to ﬁnd the location of the LFCN in 20 cadavers and 10
volunteers. Accuracy was conﬁrmed by dissection of the
cadavers, and location of the actual nerve was conﬁrmed by
using the transdermal nerve stimulators in the volunteers.
Location accuracy using anatomical landmarks was 5.3% in
cadavers and 0% in volunteers, while accuracy of the ultra-
sound was 84.2% in cadavers and 80% in volunteers. And this
is in accordance with our study as the accuracy of ultrasound-
guided procedures was 100% (7).
Hurdle et al. (6) also reported a 100% success rate in
ultrasound-guided blockage of the LFCN in 10 patients with
small anesthetic dosages of 1–8 mL. This is in agreement
with our result as we used 4–8 mL and also we agree with
Sharrock (13) who stated that reducing the amount of local
anesthetic agent used can reduce the systemic toxicity as well
as the risk of unintended blockage of the femoral or obtura-
tor nerves.
Tagliaﬁco et al. in their study on (14) 20 consecutive
patients on ultrasound-guided treatment of meralgia paresthe-
tica reported that the symptoms diminished progressively after
the ﬁrst week in 80% of patients and the remaining patients
(20%) required a further injection. This is in contrast to our
results as the symptoms disappear in 12% of patients after
the ﬁrst injection while 24% of patients needed second injec-
tion and 64% needed third injection.
5. Conclusion
Ultrasound-guided perineural injection of the lateral femoral
cutaneous nerve is quick, safe, simple, economical, and effec-
tive in percutaneous treatment of meralgia paresthetica. It
may be considered as an alternative treatment to surgery.d number of patients at baseline and successive times of LFCN
AS at second injection VAS at third injection
core (mean ± SD) No. of cases Score (mean ± SD) No. of cases
o 0.2 ± 0.2 6 No 0.2 ± 0.2 12
ild 2.5 ± 1 15 Mild 2 ± 0.5 4
oderate 6 1 Moderate 0
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